160 related articles for article (PubMed ID: 15863170)
1. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.
Kanjeekal S; Chambers A; Fung MF; Verma S
Gynecol Oncol; 2005 May; 97(2):624-37. PubMed ID: 15863170
[TBL] [Abstract][Full Text] [Related]
2. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113).
Ray-Coquard I; Hatcher H; Bompas E; Casado A; Westermann A; Isambert N; Casali PG; Pratap S; Stark D; Valverde C; Anand A; Huizing M; Floquet A; Lindner L; Hermes B; Seddon B; Coens C; Jones R; Reed N
Int J Gynecol Cancer; 2020 Oct; 30(10):1633-1637. PubMed ID: 32546554
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard I; Rizzo E; Blay JY; Casali P; Judson I; Hansen AK; Lindner LH; Dei Tos AP; Gelderblom H; Marreaud S; Litière S; Rutkowski P; Hohenberger P; Gronchi A; van der Graaf WT
Gynecol Oncol; 2016 Jul; 142(1):95-101. PubMed ID: 27208537
[TBL] [Abstract][Full Text] [Related]
6. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Adcock L; Beecham J
Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
[TBL] [Abstract][Full Text] [Related]
12. Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Hirota Y; Miyamura K; Hayata T; Miyakawa I
Gynecol Obstet Invest; 1997; 44(1):70-2. PubMed ID: 9251960
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
Pautier P; Floquet A; Gladieff L; Bompas E; Ray-Coquard I; Piperno-Neumann S; Selle F; Guillemet C; Weber B; Largillier R; Bertucci F; Opinel P; Duffaud F; Reynaud-Bougnoux A; Delcambre C; Isambert N; Kerbrat P; Netter-Pinon G; Pinto N; Duvillard P; Haie-Meder C; Lhommé C; Rey A
Ann Oncol; 2013 Apr; 24(4):1099-104. PubMed ID: 23139262
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
Cancer; 2008 Mar; 112(6):1197-205. PubMed ID: 18224666
[TBL] [Abstract][Full Text] [Related]
15. Uterine sarcoma and aromatase inhibitors: Tom Baker Cancer Centre experience and review of the literature.
Altman AD; Nelson GS; Chu P; Nation J; Ghatage P
Int J Gynecol Cancer; 2012 Jul; 22(6):1006-12. PubMed ID: 22740004
[TBL] [Abstract][Full Text] [Related]
16. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
17. [Uterine sarcoma. Retrospective analysis of a series of 22 cases].
Mage P; Chauvergne J; Bui NB; Avril A; Trojani M; Richaud P; Germain T; Maree D
J Gynecol Obstet Biol Reprod (Paris); 1984; 13(7):802-7. PubMed ID: 6549321
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
Loehrer PJ; Sledge GW; Nicaise C; Usakewicz J; Hainsworth JD; Martelo OJ; Omura G; Braun TJ
J Clin Oncol; 1989 Nov; 7(11):1655-9. PubMed ID: 2681554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
